These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 19866469)

  • 21. Osteoblasts produce soluble factors that induce a gene expression pattern in non-metastatic prostate cancer cells, similar to that found in bone metastatic prostate cancer cells.
    Fu Z; Dozmorov IM; Keller ET
    Prostate; 2002 Apr; 51(1):10-20. PubMed ID: 11920953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Osteolytic prostate cancer cells induce the expression of specific cytokines in bone-forming osteoblasts through a Stat3/5-dependent mechanism.
    Schulze J; Albers J; Baranowsky A; Keller J; Spiro A; Streichert T; Zustin J; Amling M; Schinke T
    Bone; 2010 Feb; 46(2):524-33. PubMed ID: 19796718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osteoblast-secreted WISP-1 promotes adherence of prostate cancer cells to bone via the VCAM-1/integrin α4β1 system.
    Chang AC; Chen PC; Lin YF; Su CM; Liu JF; Lin TH; Chuang SM; Tang CH
    Cancer Lett; 2018 Jul; 426():47-56. PubMed ID: 29627497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone.
    Lee Y; Schwarz E; Davies M; Jo M; Gates J; Wu J; Zhang X; Lieberman JR
    J Orthop Res; 2003 Jan; 21(1):62-72. PubMed ID: 12507581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
    Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
    Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone.
    Li ZG; Yang J; Vazquez ES; Rose D; Vakar-Lopez F; Mathew P; Lopez A; Logothetis CJ; Lin SH; Navone NM
    Oncogene; 2008 Jan; 27(5):596-603. PubMed ID: 17700537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone.
    Lu Y; Chen Q; Corey E; Xie W; Fan J; Mizokami A; Zhang J
    Clin Exp Metastasis; 2009; 26(2):161-9. PubMed ID: 19002595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p65-Dependent production of interleukin-1β by osteolytic prostate cancer cells causes an induction of chemokine expression in osteoblasts.
    Schulze J; Weber K; Baranowsky A; Streichert T; Lange T; Spiro AS; Albers J; Seitz S; Zustin J; Amling M; Fehse B; Schinke T
    Cancer Lett; 2012 Apr; 317(1):106-13. PubMed ID: 22108531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Notch3 promotes prostate cancer-induced bone lesion development via MMP-3.
    Ganguly SS; Hostetter G; Tang L; Frank SB; Saboda K; Mehra R; Wang L; Li X; Keller ET; Miranti CK
    Oncogene; 2020 Jan; 39(1):204-218. PubMed ID: 31467432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protease-activated receptor-2 dependent and independent responses of bone cells to prostate cancer cell secretory products.
    Pagel CN; Kularathna PK; Sanaei R; Young ND; Hooper JD; Mackie EJ
    Prostate; 2022 May; 82(6):723-739. PubMed ID: 35167724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis.
    Park HR; Min SK; Cho HD; Kim DH; Shin HS; Park YE
    J Korean Med Sci; 2003 Aug; 18(4):541-6. PubMed ID: 12923331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate carcinoma cells that have resided in bone have an upregulated IGF-I axis.
    Rubin J; Chung LW; Fan X; Zhu L; Murphy TC; Nanes MS; Rosen CJ
    Prostate; 2004 Jan; 58(1):41-9. PubMed ID: 14673951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases.
    Guise TA; Mohammad KS; Clines G; Stebbins EG; Wong DH; Higgins LS; Vessella R; Corey E; Padalecki S; Suva L; Chirgwin JM
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6213s-6216s. PubMed ID: 17062703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
    Goya M; Ishii G; Miyamoto S; Hasebe T; Nagai K; Yonou H; Hatano T; Ogawa Y; Ochiai A
    Prostate; 2006 Nov; 66(15):1573-84. PubMed ID: 16927388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity.
    Keller ET; Brown J
    J Cell Biochem; 2004 Mar; 91(4):718-29. PubMed ID: 14991763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Canine prostatic cancer cell line (LuMa) with osteoblastic bone metastasis.
    Elshafae SM; Dirksen WP; Alasonyalilar-Demirer A; Breitbach J; Yuan S; Kantake N; Supsavhad W; Hassan BB; Attia Z; Alstadt LB; Rosol TJ
    Prostate; 2020 Jun; 80(9):698-714. PubMed ID: 32348616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism.
    Dai J; Keller J; Zhang J; Lu Y; Yao Z; Keller ET
    Cancer Res; 2005 Sep; 65(18):8274-85. PubMed ID: 16166304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.
    Mohamedali KA; Li ZG; Starbuck MW; Wan X; Yang J; Kim S; Zhang W; Rosenblum MG; Navone NM
    Clin Cancer Res; 2011 Apr; 17(8):2328-38. PubMed ID: 21343372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct inhibitory and indirect stimulatory effects of RAGE ligand S100 on sRANKL-induced osteoclastogenesis.
    Yoshida T; Flegler A; Kozlov A; Stern PH
    J Cell Biochem; 2009 Aug; 107(5):917-25. PubMed ID: 19415676
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein.
    Dai J; Kitagawa Y; Zhang J; Yao Z; Mizokami A; Cheng S; Nör J; McCauley LK; Taichman RS; Keller ET
    Cancer Res; 2004 Feb; 64(3):994-9. PubMed ID: 14871830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.